

Supplemental Table 4 Comparison of solid tumours in *Tsc2*^{+/-} mice by histological analysis

(Wilcoxon rank-sum test)

A. Lesion number (solid tumours)

Treatment*	Number of mice	Median	Range	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	4.0	1 - 13		
Everolimus	10	3.0	0 - 4	1.65 (0.100)	2.21 (0.020)
Sorafenib	10	2.5	0 - 9	0.61 (0.540)	2.36 (0.020)
Everolimus + Sorafenib	7	0.0	0 - 2	3.02 (0.003)	

B. Lesion size (solid tumours)

Treatment*	Number of mice	Median (mm ²)	Range (mm ²)	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	2.956	0.786 - 19.314		
Everolimus	10	0.940	0 - 20.431	1.89 (0.060)	1.70 (0.090)
Sorafenib	10	4.412	0 - 29.989	0.23 (0.820)	2.29 (0.020)
Everolimus + Sorafenib	7	0.000	0 - 0.999	3.14 (0.002)	

C. Lesion cellular area (solid tumours)

Treatment*	Number of mice	Median (mm ²)	Range (mm ²)	Z (P) (compared with Vehicle)	Z (P) (compared with Everolimus+Sorafenib)
Vehicle	10	2.904	0.593 - 18.520		
Everolimus	10	0.900	0 - 17.064	1.97 (0.052)	1.70 (0.090)
Sorafenib	10	2.778	0 - 11.233	0.38 (0.700)	2.29 (0.020)
Everolimus + Sorafenib	7	0.000	0 - 0.999	2.85 (0.004)	

* Treatment was started from 11 month old and continued for two months.